首页> 外文期刊>The lancet oncology >PET-CT for response assessment and treatment adaptation in head and neck cancer.
【24h】

PET-CT for response assessment and treatment adaptation in head and neck cancer.

机译:PET-CT用于头颈癌的反应评估和治疗适应。

获取原文
获取原文并翻译 | 示例
       

摘要

Preferred treatment strategies for advanced-stage squamous cell carcinoma of the head and neck have shifted from surgery to organ-preservation approaches such as radiotherapy, which can be combined with chemotherapy or giving of biologically modifying molecules. Preclinical and clinical researchers aim to customise these treatments on the basis of biological tumour characteristics, including tumour cell proliferation, hypoxia, and apoptosis--important resistance mechanisms for cytotoxic antitumour therapy. Monitoring of these biologically relevant variables before and early during treatment could improve patient selection for specific treatment strategies and guide adaptation of treatment at an early stage. PET provides a non-invasive molecular imaging method with the potential ability to undertake repetitive non-invasive quantification of relevant tumour characteristics. We discuss the role of PET scanning and available radiopharmaceutical tracers for treatment selection, early response monitoring, and treatment adaptation in head and neck cancer.
机译:头部和颈部晚期鳞状细胞癌的首选治疗策略已从手术转向器官保存方法,例如放射疗法,可以与化学疗法或生物修饰分子结合使用。临床前和临床研究人员旨在根据生物学肿瘤特征(包括肿瘤细胞增殖,缺氧和凋亡)来定制这些治疗方法,这是细胞毒性抗肿瘤治疗的重要耐药机制。在治疗前和治疗中早期对这些生物学相关变量的监测可以改善患者对特定治疗策略的选择,并指导早期治疗的适应性。 PET提供了一种非侵入性分子成像方法,具有对相关肿瘤特征进行重复性非侵入性定量分析的潜在能力。我们讨论了PET扫描和可用的放射性药物示踪剂在头颈癌的治疗选择,早期反应监测和治疗适应性方面的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号